Anacor Pharmaceuticals, Inc. 4
4 · Anacor Pharmaceuticals, Inc. · Filed Mar 4, 2015
Insider Transaction Report
Form 4
Chanda Sanjay
VP & Interim Head of Drug Deve
Transactions
- Exercise/Conversion
Common Stock
2015-03-04$7.25/sh+4,952$35,902→ 34,039 total - Sale
Common Stock
2015-03-04$45.00/sh−4,952$222,840→ 29,087 total - Exercise/Conversion
Common Stock
2015-03-04$7.55/sh+48$362→ 29,135 total - Sale
Common Stock
2015-03-04$45.00/sh−48$2,160→ 29,087 total - Exercise/Conversion
Stock Option (right to buy)
2015-03-04$7.25/sh−4,952$35,902→ 0 totalExercise: $7.25Exp: 2018-03-26→ Common Stock (4,952 underlying) - Exercise/Conversion
Stock Option (right to buy)
2015-03-04$7.55/sh−48$362→ 13,552 totalExercise: $7.55Exp: 2020-08-20→ Common Stock (48 underlying)
Footnotes (2)
- [F1]This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option is fully vested and exercisable.